Amplia Therapeutics (Amplia Therapeutics) Other Cash Receipts from Operating Activities

: $0.39 Mil (TTM As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

Amplia Therapeutics's Other Cash Receipts from Operating Activities for the six months ended in Sep. 2023 was $0.00 Mil.

Amplia Therapeutics's Other Cash Receipts from Operating Activities for the trailing twelve months (TTM) ended in Sep. 2023 was $0.39 Mil.

Amplia Therapeutics Other Cash Receipts from Operating Activities Historical Data

The historical data trend for Amplia Therapeutics's Other Cash Receipts from Operating Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amplia Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Other Cash Receipts from Operating Activities

0.15

0.48

0.84

1.26

Amplia Therapeutics Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Other Cash Receipts from Operating Activities																-0.31	1.16	0.87	0.39	-

Amplia Therapeutics Other Cash Receipts from Operating Activities Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Other Cash Receipts from Operating Activities represents cash flow received from other operating activities in the direct cash flow method.

GuruFocus lists following items in "Cash Receipts from Operating Activities" section for non-financial companies:
Receipts from Customers
Receipts from Government Grants
Other Cash Receipts from Operating Activities

Other Cash Receipts from Operating Activities for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.39 Mil.

Amplia Therapeutics Other Cash Receipts from Operating Activities Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's Other Cash Receipts from Operating Activities provided by GuruFocus.com. Please click on the following links to see related term pages.

Amplia Therapeutics (Amplia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (OTCPK:INNMF) » Definitions » Other Cash Receipts from Operating Activities

Comparable Companies

Traded in Other Exchanges

ATX:Australia

Address

350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000

Website

https://www.ampliatx.com

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics (Amplia Therapeutics) Headlines

From GuruFocus

AACR OVARIAN CANCER CONFERENCE PRESENTATION

By PRNewswire • 10-09-2023

AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer

By PRNewswire PRNewswire • 05-29-2023

FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US

By PRNewswire • 01-18-2024